A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy

Trial Profile

A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy

Suspended
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2018

At a glance

  • Drugs Monoclonal antibody 3S193 (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Apr 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
    • 09 Dec 2017 Results (n=49) presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 12 Aug 2015 Status changed from recruiting to suspended as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top